News

The company has posted net income of $8.41m, as compared to net income of $8.91m for the year ago period. China Pharma’s income from operations was $10.42m for

The MLSC grant amount is $250,000 per year for two years, and subject to a formalized agreement between the parties, will be matched dollar for dollar by RXi,

ORAL Standard is a completed 12 month study in patients with moderate-to-severe active RA who had an inadequate response to methotrexate (MTX) and were randomized to receive tofacitinib

The new entity will serve research communities throughout India with sales and service teams that sell all Phenomenex products directly and provide timely technical support, training and seminars.

MorphoSys and OncoMed had entered into a license agreement in June 2006 to use MorphoSys’ HuCAL technology in the research and development of human therapeutic antibodies for the

Particle Sciences and Celanese EVA Performance Polymers are working to provide Particle Sciences with preferred access to VitalDose EVA polymer in early stage projects. Particle Sciences New Technologies

The company posted a net loss of $32.1m, or $0.57 per diluted share for the first quarter of 2011, compared to $34.08m, or $0.66 per diluted share, for

In clinical studies, Rasilamlo demonstrated reductions in blood pressure than Rasilez and amlodipine alone. The study results suggested that the use of single-pill combinations like Rasilamlo can provide

The US net sales increased 5% to $3.3bn in the first quarter of 2011 compared to the same period in 2010. International net sales increased 3%, or 1%